Table 2. Subgroups of patients according to the pre- and post-treatment serum LDH levels.
| Cases (n) | Pretreatment serum LDH (IU/L) |
Post-treatment serum LDH (IU/L) |
Clinical stage* (%) |
P# | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | Median | Range | I | II | III | IV | ||||
| Group 1 | 1309 | 168.6 ± 28.9 | 166.0 | 84.0–245.0 | 153.5 ± 29.1 | 151.0 | 16.0–244.0 | 62 (4.7%) | 260 (19.9%) | 634 (48.4%) | 353 (27.0%) | 0.025 |
| Group 2 | 83 | 307.6 ± 87.7 | 274.0 | 246.0–753.0 | 176.9 ± 34.9 | 174.0 | 110.0–243.0 | 0 (0.0%) | 11 (13.3%) | 33 (39.8%) | 39 (47.0%) | |
| Group 3 | 28 | 183.9 ± 26.8 | 191.5 | 140.0–241.0 | 285.4 ± 51.7 | 269.0 | 247.0–475.0 | 1 (3.0%) | 5 (17.9%) | 13 (46.4%) | 9 (32.1%) | |
| Group 4 | 8 | 367.3 ± 134.5 | 313.0 | 251.0–565.0 | 508.7 ± 517.5 | 271.0 | 245.0–1756.0 | 0 (0%) | 1 (12.5%) | 4 (50%) | 3 (37.5%) | |
LDH, lactate dehydrogenase; IU, international unit.
*According to the American Joint Committee on Cancer, 7th edition.
#P values were calculated using the chi-square test.